Cannabinoid study reveals how the brain handles fear in PTSD
NCT ID NCT02069366
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how a single dose of dronabinol (a synthetic cannabinoid) affects fear-related brain activity in people with PTSD, trauma-exposed individuals without PTSD, and healthy controls. Using brain scans, researchers measured how the drug influences fear extinction circuits. The goal is to better understand PTSD and potentially develop new treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dronabinol (a synthetic cannabinoid)
- What this could lead to
- If successful, this research could point toward new treatments for anxiety and fear-based disorders like PTSD.
- What could go wrong
- This is a small, early-stage study focused on understanding brain mechanisms, not testing a treatment. The drug is given only once, so results may not apply to real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
86 people
The number who actually took part.
- Started
-
Nov 2014
- Finished
-
Dec 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for All Participants: * Able to give informed consent * Physically and neurologically healthy \[confirmed by a comprehensive medical history\] * Age between 21-45 years old * Right-handed Inclusion Criteria for Participants with PTSD: * Current PTSD diagnosis \[related to civilian trauma\] Inclusion Criteria for Trauma-Exposed Participants without PTSD: * Experience with a civilian trauma without a PTSD diagnosis * Free of a lifetime Axis I or Axis II diagnosis Inclusion Criteria for Non-Trauma-Exposed Healthy Participants: * Free of a lifetime Axis I or Axis II diagnosis Exclusion Criteria for All Participants: * Clinically significant medical or neurological condition * Less than a high school education * Lack of fluency in English * Night shift work * Currently pregnant; planning pregnancy; or lactating * Unwilling/unable to sign informed consent document * Inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia) * Left-handed * Presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles) * Under 21 or over 45 years of age * Anticipation of a required drug test in the 4 weeks following study participation * Positive urine drug screen and/or alcohol breathalyzer * Current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances \[dronabinol/marijuana/cannabis/thc, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide\] * Participation in an experiment involving white noise bursts or shocks in the last 6 months Exclusion Criteria for Participants with PTSD: * Primary comorbid anxiety disorder (defined by which disorder was the more debilitating and clinically salient) * Life history of bipolar disorder, schizophrenia, or presence of an organic mental syndrome, mental retardation, or pervasive developmental disorder * Current or in the past 6 months alcohol/drug abuse of dependence * Current or in the past 6 months major depressive disorder * Current suicidal ideation * Diagnosis of an Axis II personality disorder * Concomitant treatments with psychotropic/psychoactive medication \[including beta-adrenergic blockers, selective serotonin reuptake inhibitor (SSRI), benzodiazepines, tricyclic or monoamine oxidase inhibitor (MAOI) antidepressants, lithium, antiepileptic/anticonvulsants, neuroleptics/antipsychotics, etc.) or in the past two weeks \[8 weeks for fluoxetine and 4 weeks for MAOIs) before screening (Visit 1) * currently receiving exposure-based therapy for PTSD Exclusion Criteria for Trauma-Exposed Participants without PTSD and Non-Trauma Exposed Healthy Participants: * Current or past Axis I psychiatric disorder \[including alcohol/substance abuse of dependence disorder\]
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Post traumatic stress disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eugene Applebaum College of Pharmacy and Health Sciences
Detroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five sessions to quiet trauma nightmares in bipolar disorder
- Can training hospital staff in Trauma-Informed care make childbirth safer?
- Scientists probe brain's reward system in mental illness
- Can a mindfulness class help veterans with concussion and PTSD?
- Can MDMA plus therapy help veterans fight both PTSD and alcohol addiction?
- Can talk therapies quiet the trauma of violence?